| ［1］ |
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10): 1335.
|
| ［2］ |
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7): 844–860.
|
| ［3］ |
Sugimoto M. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading[J]. World J Gastroenterol, 2015, 21(26): 8118.
|
| ［4］ |
Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size[J]. Ann Surg Oncol, 2013, 20(9): 2815–2821.
|
| ［5］ |
Lopez-Ramirez F, Soleimani S, Azadi JR, et al. Radiomics machine learning algorithm facilitates detection of small pancreatic neuroendocrine tumors on CT[J]. Diagn Interv Imaging, 2025, 106(1): 28–40.
|
| ［6］ |
Li J, Lu J, Liang P, et al. Differentiation of atypical pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas: using whole tumor CT texture analysis as quantitative biomarkers[J]. Cancer Med, 2018, 7(10): 4924–4931.
|
| ［7］ |
Reinert CP, Baumgartner K, Hepp T, et al. Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase[J]. Abdom Radiol (NY), 2020, 45(3): 750–758.
|
| ［8］ |
Yu H, Huang Z, Li M, et al. Differential diagnosis of nonhypervascular pancreatic neuroendocrine neoplasms from pancreatic ductal adenocarcinomas, based on computed tomography radiological features and texture analysis[J]. Acad Radiol, 2020, 27(3): 332–341.
|
| ［9］ |
Zhang T, Xiang Y, Wang H, et al. Radiomics combined with multiple machine learning algorithms in differentiating pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumor: more hands produce a stronger flame[J]. J Clin Med, 2022, 11(22): 6789.
|
| ［10］ |
Shen K, Su W, Liang C, et al. Differentiating small (< 2 cm) pancreatic ductal adenocarcinoma from neuroendocrine tumors with multiparametric MRI-based radiomic features[J]. Eur Radiol, 2024, 34(12): 7553–7563.
|
| ［11］ |
Shi YJ, Zhu HT, Li XT, et al. Histogram array and convolutional neural network of DWI for differentiating pancreatic ductal adenocarcinomas from solid pseudopapillary neoplasms and neuroendocrine neoplasms[J]. Clin Imaging, 2023, 96: 15–22.
|
| ［12］ |
Patel N, Barbieri A, Gibson J. Neuroendocrine tumors of the gastrointestinal tract and pancreas[J]. Surg Pathol Clin, 2019, 12(4): 1021–1044.
|
| ［13］ |
Li X, Zhu H, Qian X, et al. MRI texture analysis for differentiating nonfunctional pancreatic neuroendocrine neoplasms from solid pseudopapillary neoplasms of the pancreas[J]. Acad Radiol, 2020, 27(6): 815–823.
|
| ［14］ |
Song T, Zhang QW, Duan SF, et al. MRI-based radiomics approach for differentiation of hypovascular non-functional pancreatic neuroendocrine tumors and solid pseudopapillary neoplasms of the pancreas[J]. BMC Med Imaging, 2021, 21(1): 36.
|
| ［15］ |
Shi YJ, Zhu HT, Liu YL, et al. Radiomics analysis based on diffusion kurtosis imaging and T2 weighted imaging for differentiation of pancreatic neuroendocrine tumors from solid pseudopapillary tumors[J]. Front Oncol, 2020, 10: 1624.
|
| ［16］ |
Chen J, Yang Y, Liu Y, et al. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation[J]. World J Surg Oncol, 2021, 19(1): 11.
|
| ［17］ |
Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-Functional pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2016, 103(2): 153–171.
|
| ［18］ |
Mapelli P, Bezzi C, Palumbo D, et al. 68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours[J]. Eur J Nucl Med Mol Imaging, 2022, 49(7): 2352–2363.
|
| ［19］ |
Benedetti G, Mori M, Panzeri MM, et al. CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors[J]. Radiol Med, 2021, 126(6): 745–760.
|
| ［20］ |
Ahmed TM, Zhu Z, Yasrab M, et al. Preoperative prediction of lymph node metastases in nonfunctional pancreatic neuroendocrine tumors using a combined CT radiomics–clinical model[J]. Ann Surg Oncol, 2024, 31(12): 8136–8145.
|
| ［21］ |
Gu W, Chen Y, Zhu H, et al. Development and validation of CT-based radiomics deep learning signatures to predict lymph node metastasis in non-functional pancreatic neuroendocrine tumors: A multicohort study[J]. eClinicalMedicine, 2023, 65: 102269.
|
| ［22］ |
Li J, Huang L, Liao C, et al. Two machine learning-based nomogram to predict risk and prognostic factors for liver metastasis from pancreatic neuroendocrine tumors: A multicenter study[J]. BMC Cancer, 2023, 23(1): 529.
|
| ［23］ |
Pan M, Yang Y, Teng T, et al. Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: A large cohort study[J]. BMC Gastroenterol, 2021, 21(1): 101.
|
| ［24］ |
Ma M, Gu W, Liang Y, et al. A novel model for predicting postoperative liver metastasis in R0 resected pancreatic neuroendocrine tumors: integrating computational pathology and deep learning-radiomics[J]. J Transl Med, 2024, 22(1): 768.
|
| ［25］ |
Takumi K, Fukukura Y, Higashi M, et al. Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade[J]. Eur J Radiol, 2015, 84(8): 1436–1443.
|
| ［26］ |
Canellas R, Burk KS, Parakh A, et al. Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis[J]. AJR Am J Roentgenol, 2018, 210(2): 341–346.
|
| ［27］ |
Liang W, Yang P, Huang R, et al. A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors[J]. Clin Cancer Res, 2019, 25(2): 584–594.
|
| ［28］ |
Gu D, Hu Y, Ding H, et al. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: A multicenter study[J]. Eur Radiol, 2019, 29(12): 6880–6890.
|
| ［29］ |
Bian Y, Jiang H, Ma C, et al. CT-based radiomics score for distinguishing between grade 1 and grade 2 nonfunctioning pancreatic neuroendocrine tumors[J]. AJR Am J Roentgenol, 2020, 215(4): 852–863.
|
| ［30］ |
Zhao Z, Bian Y, Jiang H, et al. CT-radiomic approach to predict G1/2 nonfunctional pancreatic neuroendocrine tumor[J]. Acad Radiol, 2020, 27(12): e272-e281.
|
| ［31］ |
Zhang T, Zhang Y, Liu X, et al. Application of radiomics analysis based on CT combined with machine learning in diagnostic of pancreatic neuroendocrine tumors patient’s pathological grades[J]. Front Oncol, 2021, 10: 521831.
|
| ［32］ |
Ye JY, Fang P, Peng ZP, et al. A radiomics-based interpretable model to predict the pathological grade of pancreatic neuroendocrine tumors[J]. Eur Radiol, 2023, 34(3): 1994–2005.
|
| ［33］ |
Bian Y, Li J, Cao K, et al. Magnetic resonance imaging radiomic analysis can preoperatively predict G1 and G2/3 grades in patients with NF-pNETs[J]. Abdom Radiol (NY), 2021, 46(2): 667–680.
|
| ［34］ |
Zhu HB, Zhu HT, Jiang L, et al. Radiomics analysis from magnetic resonance imaging in predicting the grade of nonfunctioning pancreatic neuroendocrine tumors: A multicenter study[J]. Eur Radiol, 2023, 34(1): 90–102.
|
| ［35］ |
Liu C, Bian Y, Meng Y, et al. Preoperative prediction of G1 and G2/3 grades in patients with nonfunctional pancreatic neuroendocrine tumors using multimodality imaging[J]. Acad Radiol, 2022, 29(4): e49-e60.
|
| ［36］ |
Ma J, Wang X, Tang M, et al. Preoperative prediction of pancreatic neuroendocrine tumor grade based on 68Ga-DOTATATE PET/CT[J]. Endocrine, 2023, 83(2): 502–510.
|
| ［37］ |
Yan Q, Chen Y, Liu C, et al. Predicting histologic grades for pancreatic neuroendocrine tumors by radiologic image-based artificial intelligence: A systematic review and meta-analysis[J]. Front Oncol, 2024, 14: 1332387.
|
| ［38］ |
Song C, Wang M, Luo Y, et al. Predicting the recurrence risk of pancreatic neuroendocrine neoplasms after radical resection using deep learning radiomics with preoperative computed tomography images[J]. Ann Transl Med, 2021, 9(10): 833–833.
|
| ［39］ |
Homps M, Soyer P, Coriat R, et al. A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors[J]. Eur J Endocrinol, 2023, 189(4): 476–484.
|
| ［40］ |
Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase Ⅲ RADIANT-3 study[J]. J Clin Oncol, 2016, 34(32): 3906–3913.
|
| ［41］ |
Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase Ⅲ randomized study[J]. Ann Oncol, 2017, 28(2): 339–343.
|
| ［42］ |
Caruso D, Polici M, Rinzivillo M, et al. CT-based radiomics for prediction of therapeutic response to everolimus in metastatic neuroendocrine tumors[J]. Radiol Med, 2022, 127(7): 691–701.
|
| ［43］ |
Lamarca A, Barriuso J, Kulke M, et al. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: An alternative to the current RECIST-defined response[J]. Br J Cancer, 2018, 118(2): 181–188.
|
| ［44］ |
Chen L, Wang W, Jin K, et al. Special issue “The advance of solid tumor research in China”: prediction of sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors[J]. Int J Cancer, 2023, 152(1): 90–99.
|
| ［45］ |
Öksüz M Ö, Winter L, Pfannenberg C, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?[J]. Diagn Interv Imaging, 2014, 95(3): 289–300.
|
| ［46］ |
Cook GJR, O’Brien ME, Siddique M, et al. Non-small cell lung cancer treated with erlotinib: heterogeneity of 18F-FDG uptake at PET-association with treatment response and prognosis[J]. Radiology, 2015, 276(3): 883–893.
|
| ［47］ |
Werner RA, Ilhan H, Lehner S, et al. Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy[J]. Mol Imaging Biol, 2019, 21(3): 582–590.
|
| ［48］ |
Önner H, Abdülrezzak Ü, Tutuş A. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?[J]. Nucl Med Commun, 2020, 41(10): 1034–1039.
|
| ［49］ |
Weber M, Kessler L, Schaarschmidt B, et al. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient[J]. BMC Cancer, 2020, 20(1): 326.
|
| ［50］ |
Kocak B, Bulut E, Bayrak ON, et al. Negative results in radiomics research (NEVER): A meta-research study of publication bias in leading radiology journals[J]. Eur J Radiol, 2023, 163: 110830.
|